Tuberous sclerosis complex (TSC) is a phenotypically heterogeneous autosomal dominant epilepsy, neuropsychiatric, and tumoral predisposition disease, occurring due to germline variants in the TSC1 or TSC2 genes. Despite an improving understanding of the varied phenotypes TSC may present with, there remains an incomplete understanding of the disease trajectory and genotype-phenotype relationship in this disorder. We sought to examine whether an unbiased clustering approach could uncover subgroups of disease trajectories in TSC and enhance understanding of genotype-phenotype correlation. In this observational, prospective, multicentre natural history cohort of patients with confirmed diagnosis of TSC (TSC Alliance Natural History Database), data collected from 2006 - 2022 was used to identify groups of co-occurring phenotypes. This was a multicentre study involving 18 TSC clinical network centres in the US. 947 individuals were included, all of whom had a clinical diagnosis of tuberous sclerosis complex. Each patient was required to have complete characterization of 29 phenotype features associated with TSC. The primary outcomes were consensus clusters of clinical features defining subgroups of patients with TSC and their association with genotype. 947 individuals (50% male) across the TSC Alliance Natural History Database were included in this study, and 29 clinical features were used to define clusters of phenotypes to define disease trajectories. Four reproducible and distinct disease subgroups were identified: angiomyolipoma-predominant TSC (cluster 1), TSC with infantile spasms (cluster 2), neuropsychiatric TSC (cluster 3), and a milder phenotype of TSC (cluster 4). Variants in the rho domain of hamartin and the TSC1 binding domain of tuberin preferentially associated with cluster 1, with increased likelihood of angiomyolipomas, dermatologic findings, and subependymal giant cell astrocytoma. Four distinct disease subgroups exist in TSC and differentially associate with variant location, informing deep genotype-phenotype correlation in TSC with potential impact in personalizing disease surveillance, treatment, and clinical trial endpoint choice. Additional prospective data are needed to confirm these findings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/brain/awaf072 | DOI Listing |
Acta Crystallogr E Crystallogr Commun
March 2025
A new cobalt complex, bis-[tris-(amino-thio-urea)cobalt(III)] bis-[2-(carb-oxy-methyl)-2-hy-droxy-butane-dioato]cobalt(II) tetra-nitrate tetra-hydrate, [Co(CHNS)][Co(CHO)](NO)·2HO, designated as [Co(tsc)][Co(cit)](NO)·4HO, was synthesized. Two crystallographically independent cobalt centers are present. In the first, the central metal atom is chelated by three thio-semicarbazide ligands in a bidentate fashion whereas the second, positioned on a crystallographic inversion center, is hexa-coordinated by two citrate anions in a distorted octa-hedral geometry.
View Article and Find Full Text PDFClin Chim Acta
March 2025
LIFE Leipzig Research Center for Civilization Diseases, University of Leipzig 04103 Leipzig, Germany.
Background: Vascular endothelial growth factor D (VEGF-D) is a growth-factor involved in the development of blood vessels and lymphatics in tissues all over the human body. Interestingly, VEGF-D serum levels are increased in certain tumor entities. For tuberous sclerosis complex (TSC), a rare genetic disease associated with (benign) tumor growth, VEGF-D is already implemented as a diagnostic and therapeutic biomarker to monitor onset and progress of lymphangioleiomyomatosis (LAM), one of the noncancerous tumor manifestations in mainly female adult TSC patients.
View Article and Find Full Text PDFJ Intellect Disabil Res
March 2025
Neuroscience and Mental Health Innovation Institute, Cardiff, UK.
Background: Tuberous sclerosis complex (TSC) is a genetic condition caused by mutations in either TSC1 or TSC2 genes, affecting around two million people globally. This study aims to examine causes of death in TSC and explore factors contributing to mortality in people with TSC in the United Kingdom in recent years following updated management and surveillance guidelines for the condition.
Methods: Comprehensive analysis of the available medical records of the people seen at the largest lifespan TSC clinic in the United Kingdom who passed away between 2016 and 2022 was conducted.
Clin Psychol Psychother
March 2025
Psychology Department, York University, Toronto, Ontario, Canada.
Objective: This single-arm effectiveness study explored changes in trauma-related symptoms-including dissociation, depression, anxiety, sexual issues and sleep disturbances-throughout a multimodal, phased trauma intervention, to explore treatment response in real-world settings with varied populations and complex clinical presentations, as well as varied degrees of clinician experience.
Method: Symptom change was assessed among participants undergoing a triphasic trauma therapy called trauma practice. Data were collected at five time points: pretreatment (n = 41), Phase 1 (n = 37), Phase 2 (n = 25), Phase 3 (n = 20) and follow-up (n = 16).
Am J Clin Dermatol
March 2025
Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong Province, China.
Background: There are limited data on clinical outcomes and prognosis factors for bullous pemphigoid (BP) at long-term follow-up.
Objective: We aimed to investigate the clinical outcomes and prognostic factors in BP patients.
Methods: This retrospective study was performed between January 1, 2009 and December 31, 2023 in Shandong Province, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!